Amoy Diagnostics

Jan 29, 2019

AmoyDx, Sanomics Ink Deal for Multigene Mutation Detection Kit

AmoyDx's kit is designed to detect hotspot mutations/fusions in nine genes to help guide treatment decisions for non-small cell lung cancer patients.

Oct 12, 2018

AmoyDx Lung Cancer CDx Approved in South Korea

The companion diagnostic for Pfizer's Xalkori identifies 14 ROS1 gene fusions by analyzing tumor messenger RNA from human tumor tissue or body fluids.

Jan 29, 2018

AmoyDx, Medikonia Ink MDx Distribution Deal

AmoyDx's molecular diagnostics tests, powered by its ADx-ARMS and Super-ARMS technologies, will be made available in Hong Kong and Macau.

Jan 22, 2018

AmoyDx Wins Chinese Approval for Lung Cancer Liquid Biopsy CDx

The real-time PCR-based test is designed to identify EGFR mutations in circulating tumor DNA in plasma samples.

May 16, 2017

Amoy Dx Partners With Canbridge on CDx Development

Amoy will supply its CD95 IHC and CpG2 qPCR kits to develop a companion diagnostic for Canbridge's lead product targeting recurrent glioblastoma multiforme.

Feb 03, 2017

Japan Regulators Approve AmoyDx's Lung Cancer CDx

The firm's ROS1 gene fusion kit was approved as a companion diagnostic for Pfizer's Xalkori.

Jul 28, 2016

Merck KGaA, AmoyDx Partner on Colorectal Cancer Test for Chinese Market

The test, which will be based on AmoyDx's proprietary real-time PCR technology, will identify cancer-associated mutations in the RAS gene family.

Oct 01, 2015

AmoyDx, Illumina Partner to Develop NGS Cancer Diagnostics for Chinese Clinical Oncology Market

AmoyDx will develop and commercialize a series of oncology tests that use Illumina NGS technology, including the firm's TruSight Tumor 15 panel.

Oct 24, 2014